Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL6 | P41182 | 8/20 | 0.55 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.52 |
| ▸ | SYK | P43405 | 9/20 | 0.51 |
| ▸ | AURKA | O14965 | 2/20 | 0.51 |
| ▸ | EGFR | P00533 | 2/20 | 0.47 |
| ▸ | ITK | Q08881 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2104215 | 0.85 | SYK (0.60) | BCL6NCOR2SYKAURKAEGFR | |
| SCHEMBL2100648 | 0.85 | BCL6 (0.49) | BCL6NCOR2SYKAURKA | |
| SCHEMBL12389655 | 0.85 | SYK (0.50) | BCL6NCOR2SYKAURKAITK | |
| SCHEMBL2100643 | 0.83 | BCL6 (0.72) | BCL6NCOR2SYKAURKA | |
| SCHEMBL2102324 | 0.79 | SYK (0.62) | BCL6NCOR2SYKAURKA | |
| SCHEMBL27631776 | 0.79 | BCL6 (0.52) | BCL6NCOR2SYKAURKAEGFR | |
| SCHEMBL2104265 | 0.78 | BCL6 (0.46) | BCL6NCOR2SYKAURKA | |
| SCHEMBL2101164 | 0.77 | BCL6 (0.59) | BCL6SYKAURKAEGFRITK | |
| SCHEMBL2101829 | 0.77 | BCL6 (0.67) | BCL6NCOR2SYKAURKA | |
| SCHEMBL656977 | 0.77 | SYK (0.69) | SYKAURKAEGFRITK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9598432-B2 | 2,4-pyrimidinediamine compounds and uses as anti-proliferative agents | RIGEL PHARMACEUTICALS, INC. (US) | 2017-03-21 | — | — | US | disclosed |
| US-20150011002-A1 | 2,4-Pyrimidinediamine Compounds And Uses As Anti-Proliferative Agents | RIGEL PHARMACEUTICALS, INC. (US) | 2015-01-08 | — | — | US | disclosed |
| US-8809341-B2 | 2,4-pyrimidinediamine compounds and uses as anti-proliferative agents | RIGEL PHARMACEUTICALS, INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-20110190271-A1 | 2,4-Pyrimidinediamine Compounds and Uses as Anti-Proliferative Agents | RIGEL PHARMACEUTICALS, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| US-7884111-B2 | 2,4-pyrimidinediamine compounds and uses as anti-proliferative agents | RIGEL PHARMACEUTICALS, INC. (US) | 2011-02-08 | — | — | US | disclosed |
| US-7884111-B2 | 2,4-pyrimidinediamine compounds and uses as anti-proliferative agents | RIGEL PHARMACEUTICALS, INC. (US) | 2011-02-08 | — | — | US | disclosed |
| US-20080027045-A1 | 2,4-Pyrimidinediamine Compounds And Uses As Anti-Proliferative Agents | RIGEL PHARMACEUTICALS, INC. (US) | 2008-01-31 | — | — | US | disclosed |
| US-20080027045-A1 | 2,4-Pyrimidinediamine Compounds And Uses As Anti-Proliferative Agents | RIGEL PHARMACEUTICALS, INC. (US) | 2008-01-31 | — | — | US | disclosed |
| US-20080021020-A1 | 2,4-Pyrimidinediamine Compounds And Uses As Anti-Proliferative Agents | RIGEL PHARMACEUTICALS, INC. (US) | 2008-01-24 | — | — | US | disclosed |
| US-20080021020-A1 | 2,4-Pyrimidinediamine Compounds And Uses As Anti-Proliferative Agents | RIGEL PHARMACEUTICALS, INC. (US) | 2008-01-24 | — | — | US | disclosed |
| US-20080009484-A1 | 2,4-Pyrimidinediamine Compounds And Uses As Anti-Proliferative Agents | RIGEL PHARMACEUTICALS, INC. (US) | 2008-01-10 | — | — | US | disclosed |
| US-20080009484-A1 | 2,4-Pyrimidinediamine Compounds And Uses As Anti-Proliferative Agents | RIGEL PHARMACEUTICALS, INC. (US) | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009484-A1 | 2,4-Pyrimidinediamine Compounds And Uses As Anti-Proliferative Agents | MKI67, TYMP, PCNA | BCL6 781/4885NCOR2 1953/4885SYK 4427/4885 |
| US-20080027045-A1 | 2,4-Pyrimidinediamine Compounds And Uses As Anti-Proliferative Agents | MKI67, TYMP, PCNA | BCL6 781/4885NCOR2 1953/4885SYK 4427/4885 |
| US-20080021020-A1 | 2,4-Pyrimidinediamine Compounds And Uses As Anti-Proliferative Agents | MKI67, TYMP, PCNA | BCL6 781/4885NCOR2 1953/4885SYK 4427/4885 |
| US-20110190271-A1 | 2,4-Pyrimidinediamine Compounds and Uses as Anti-Proliferative Agents | MKI67, TYMP, PCNA | BCL6 781/4885NCOR2 1953/4885SYK 4427/4885 |
| US-20150011002-A1 | 2,4-Pyrimidinediamine Compounds And Uses As Anti-Proliferative Agents | MKI67, TYMP, PCNA | BCL6 781/4885NCOR2 1953/4885SYK 4427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.